In the phase 3 NEAT trial, eDSP was well tolerated but did not significantly reduce neurological symptoms in patients with ataxia-telangiectasia. Topline data were announced from a phase 3 trial ...

Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A few years ago, I was out hiking when the world suddenly tilted. The ground felt unsteady, and I was sure I was about to fall. What followed was a parade of specialists and a battery of uncomfortable ...

Cerebellum (Latin: "little brain") in orange. Cerebellar means "relating to the cerebellum." Source: 3dMediSphere / Shutterstock Since the 1970s, I've been intrigued by the cerebellum's role in peak ...

Not only can such devices be awkward, many people also perceive them as being stigmatizing. That's where the GyroPack backpack comes in. The device was first developed by Prof. Heike Vallery's team at ...

An innovative backpack, incorporating aerospace technology, shows promise as a balance aid for patients with the movement disorder ataxia. Research conducted by Radboud university medical center, in ...

Ataxia telangiectasia (AT) is a rare genetic condition that people inherit from their parents. AT affects the part of the brain that controls movement and coordination. Ataxia is when a person has ...

BAERs is the most used electrophysiological test in veterinary medicine to evaluate the normality of the auditory system (Besalti et al., 2008; Cvejic et al., 2009, Colson et al., 2012). BAERs are the ...

Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with ...